This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
5-Amino-1-methylquinolinium is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor studied for its ability to reprogram fat cell metabolism. By blocking NNMT — an enzyme that consumes NAD+ and SAM to methylate nicotinamide — it preserves intracellular NAD+ in adipose tissue, activates SIRT1, and shifts white fat cells toward oxidative metabolism. Not technically a peptide, but consistently included in research peptide catalogs for its overlapping applications.
NNMT (nicotinamide N-methyltransferase) is highly expressed in white adipose tissue, liver, and skeletal muscle. Its job is to methylate nicotinamide — a metabolic byproduct of NAD+ consumption — converting it into 1-methylnicotinamide (MNA). The inputs it consumes to do this are NAD+ (indirectly, as nicotinamide is derived from NAD+ breakdown) and SAM (S-adenosylmethionine), the universal methyl donor.
In obese adipose tissue, NNMT is significantly upregulated. The consequences: intracellular NAD+ is depleted in fat cells, SIRT1 (an NAD+-dependent deacetylase with roles in fat oxidation and metabolic rate) is underactivated, and the adipocyte sits in a low-energy, high-storage state. 5-Amino-1MQ was identified through high-throughput screening as a potent, selective inhibitor of NNMT — disrupting this cycle at the source.
What makes 5-Amino-1MQ scientifically distinctive is that it targets metabolic dysfunction at the adipose tissue level rather than suppressing appetite or altering systemic hormones. The result in mouse studies was fat mass loss without changes to food intake, lean mass, or systemic SAM/methylation chemistry — suggesting the effect is adipose-specific rather than a broad metabolic override.
Normal: NNMT consumes SAM to methylate nicotinamide → MNA. NAD+ depleted in adipocytes, SIRT1 underactive, fat stored. With 5-Amino-1MQ blocking NNMT: nicotinamide is salvaged back to NAD+ via NAMPT, intracellular NAD+ rises, SIRT1 activates, adipocytes shift toward oxidative metabolism. SAM is preserved for other methylation reactions.
In the primary Nature Communications study, diet-induced obese mice on 5-Amino-1MQ lost ~6% body fat over 9 days with no change in food intake. Fat mass reduction was specific to adipose tissue; lean mass was preserved throughout.
By blocking NNMT, NAD+ precursors (nicotinamide) are spared from methylation and returned to the NAD+ salvage pathway. Intracellular NAD+ rises in adipocytes — enabling NAD+-dependent enzymes like SIRT1 and PARP to function at higher capacity.
SIRT1 is a longevity-associated NAD+-dependent deacetylase that regulates fat oxidation, mitochondrial biogenesis, and metabolic flexibility. Elevated NAD+ from NNMT inhibition allows SIRT1 to operate at its full enzymatic capacity in fat tissue.
NNMT is most highly expressed in white adipose tissue. 5-Amino-1MQ's effect appears concentrated in adipocytes rather than systemically distributed — which may explain why lean mass was spared and why no adverse metabolic effects were observed in mouse data.
Unlike GLP-1 receptor agonists or centrally-acting compounds, 5-Amino-1MQ did not alter food intake in study animals. The fat loss mechanism is metabolic reprogramming of existing adipose tissue — not reduced energy input. This is a meaningfully different mechanism.
Blocking NNMT's consumption of SAM (the methyl donor) theoretically preserves SAM for other methylation reactions — DNA methylation, neurotransmitter synthesis, creatine production. Whether this has practical downstream effects in humans is not established.
Diet-induced obese mice lost approximately 6% body fat over 9 days of treatment in the primary study — without caloric restriction or changes to food intake. Lean mass unchanged.
Kaspar et al., Nature Communications. Identified 5-Amino-1MQ through systematic NNMT inhibitor screening. Replicated adipose-specific metabolic effects with multiple dosing approaches in rodent models.
No registered human trials. Dosing in research community extrapolated from mouse data. Human pharmacokinetics, dose-response, and tissue distribution are not established in clinical literature.
5-Amino-1MQ is typically administered orally or subcutaneously in the research community. Mouse study dosing extrapolated to human scale (allometric scaling from 50–100mg/kg in mice) yields a wide estimated range — human oral bioavailability is not well characterized, which is why some researchers prefer SC injection for more predictable delivery. This compound is among the more novel in our catalog; dosing conventions have not converged as they have for longer-studied peptides.
| Protocol | Dose | Frequency | Notes |
|---|---|---|---|
| Oral (common) | 50–100mg | Once daily | Most referenced approach in the research community. Oral bioavailability in humans is not established — actual systemic delivery is uncertain. Take with food to reduce GI irritation. |
| SC injection | 1–2mg SC | Once daily | Lower dose than oral due to bypassing first-pass metabolism. Some researchers prefer this route for more reliable delivery. Abdominal injection common. |
| Cycle length | — | — | No established cycle protocol. Mouse studies used 7–14 day treatment periods. Research community conventions vary widely — this is an early-stage compound without consensus dosing. |
5-Amino-1MQ's NAD+-sparing mechanism makes it naturally complementary to NAD+ precursors and other metabolic research compounds. Researchers interested in adipose tissue reprogramming often combine it with compounds targeting related pathways.
5mg vials. Finnrick-verified purity, lot-specific COA, ships in 24 hours.
Begin Protocol Intake View All ProtocolsMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.